Population Pharmacokinetics of Amlodipine and Telmisartan Following Oral Administration of a Single-Pill Fixed-Dose Combination in Healthy Korean Male Subjects.

BACKGROUND AND

OBJECTIVE

Fixed-dose combinations (FDCs) of amlodipine and telmisartan are widely used for hypertension management owing to their efficacy and improved adherence. This study aimed to characterize the pharmacokinetics (PKs) of both drugs after a single oral dose of a single-pill FDC of amlodipine 5 mg/telmisartan 80 mg in healthy Korean males.

METHODS

A total of 681 amlodipine and 1500 telmisartan plasma concentrations from 32 healthy Korean males were retrospectively obtained from a bioequivalence study. Noncompartmental analysis and population analysis were conducted using WinNonLin™ (Pharsight Corp., Mountain View, CA, USA) and NONMEM® (ICON Development Solutions, Hanover, MD, USA), respectively. A two-compartment model with first-order absorption and elimination was selected for both drugs. Covariate screening using a stepwise approach evaluated 38 demographic and clinical factors.

RESULTS

Amlodipine exhibited a longer half-life and a larger apparent volume of distribution than telmisartan. Telmisartan PKs showed high interindividual (45.9% for absorption rate constant, 45.3% for apparent volume of distribution of the central compartment [V1/F], and 40.9% for apparent clearance [CL/F]), interoccasion (53.7% for V1/F), and residual (80.3%) variabilities. Preliminary covariate analysis suggested that body surface area and age potentially influenced V1/F and CL/F for amlodipine, while height, smoking status, and total bilirubin levels were associated with telmisartan V1/F and CL/F.

CONCLUSIONS

To our knowledge, this is the first population PK study to characterize the PKs of amlodipine and telmisartan co-administered as a single-pill FDC and to identify preliminary covariates that may influence their PK profiles.